Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).

NCT07476872 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

cGVHD
HSCT

Interventions

DRUG: Gecacitinib

Sponsor

Institute of Hematology & Blood Diseases Hospital, China